Astellas Pharma Inc. (OTCMKTS:ALPMY) Sees Significant Growth in Short Interest

Astellas Pharma Inc. (OTCMKTS:ALPMY) was the target of a significant increase in short interest during the month of July. As of July 31st, there was short interest totaling 70,629 shares, an increase of 69.3% from the July 15th total of 41,707 shares. Based on an average daily volume of 401,906 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.0% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Separately, Zacks Research cut shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold”.

Astellas Pharma Stock Down 2.6%

Shares of OTCMKTS ALPMY opened at $14.33 on Tuesday. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.90 and a current ratio of 1.17. The firm has a market capitalization of $25.93 billion, a price-to-earnings ratio of 10.91 and a beta of 0.08. The stock has a 50 day moving average price of $13.60 and a 200 day moving average price of $14.65. Astellas Pharma has a 52-week low of $10.03 and a 52-week high of $17.35.

Astellas Pharma Company Profile

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).